CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. 1997

J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
Division of Human Retrovirology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

Several members of the chemokine receptor family are used together with CD4 for HIV-1 entry into target cells. T cell line-tropic (T-tropic) HIV-1 viruses use the chemokine receptor CXCR4 as a co-receptor, whereas macrophage-tropic (M-tropic) primary viruses use CCR5 (refs 2-6). Individuals with defective CCR5 alleles exhibit resistance to HIV-1 infection, suggesting that CCR5 has an important role in vivo in HIV-1 replication. A subset of primary viruses can use CCR3 as well as CCR5 as a co-receptor, but the in vivo contribution of CCR3 to HIV-1 infection and pathogenesis is unknown. HIV-1 infects the central nervous system (CNS) and causes the dementia associated with AIDS. Here we report that the major target cells for HIV-1 infection in the CNS, the microglia, express both CCR3 and CCR5. The CCR3 ligand, eotaxin, and an anti-CCR3 antibody inhibited HIV-1 infection of microglia, as did MIP-1beta, which is a CCR5 ligand. Our results suggest that both CCR3 and CCR5 promote efficient infection of the CNS by HIV-1.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008156 Luciferases Enzymes that oxidize certain LUMINESCENT AGENTS to emit light (PHYSICAL LUMINESCENCE). The luciferases from different organisms have evolved differently so have different structures and substrates. Luciferase
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015686 Gene Products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesized as protein precursors (POLYPROTEINS) and later cleaved into the final viral envelope glycoproteins by a viral protease. env Gene Products,env Polyproteins,env Protein,env Antigens,env Glycoproteins,env Polyprotein,Antigens, env,Polyprotein, env,Polyproteins, env

Related Publications

J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
June 1996, Cell,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
March 2009, The Journal of general virology,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
April 1998, Journal of virology,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
September 2002, Current drug targets. Infectious disorders,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
May 2002, Molecular human reproduction,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
June 2005, The British journal of ophthalmology,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
January 1999, Journal of virology,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
December 2007, Medical microbiology and immunology,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
January 2017, PloS one,
J He, and Y Chen, and M Farzan, and H Choe, and A Ohagen, and S Gartner, and J Busciglio, and X Yang, and W Hofmann, and W Newman, and C R Mackay, and J Sodroski, and D Gabuzda
January 2019, Journal of AIDS and HIV treatment,
Copied contents to your clipboard!